Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408466 | 0.85 | GPR35 (0.47) | GPR35NPC1RAB9AMAPTABCG2 | |
| SCHEMBL13300574 | 0.81 | ABCG2 (0.52) | GPR35NPC1RAB9AKDM4ETDP1 | |
| SCHEMBL7432239 | 0.79 | GPR35 (0.46) | GPR35NPC1RAB9AKDM4ETDP1 | |
| SCHEMBL6784145 | 0.76 | TERT (0.61) | NPC1RAB9AKDM4EMAPTGAA | |
| SCHEMBL7436468 | 0.76 | NPC1 (0.56) | NPC1RAB9AMAPTABCG2ALDH1A1 | |
| SCHEMBL23796603 | 0.73 | NPC1 (0.41) | NPC1RAB9AKDM4EMAPTKCNK2 | |
| SCHEMBL3279060 | 0.73 | HCAR2 (0.47) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL3745750 | 0.73 | HCAR2 (0.52) | MEN1KMT2A | |
| SCHEMBL3279047 | 0.73 | HCAR2 (0.47) | NPC1RAB9AKDM4EMAPTALDH1A1 | |
| SCHEMBL4422766 | 0.73 | GPR35 (0.52) | GPR35NPC1RAB9ATDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| CN-1048239-C | Naphthalene deriv. | TEIJIN LTD (JP) | 2000-01-12 | — | — | CN | disclosed |
| CN-1153511-A | Naphthalene deriv. | TEIJIN LTD (JP) | 1997-07-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | GPR35 3306/4885NPC1 987/4885RAB9A 1032/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | GPR35 2790/4885NPC1 3207/4885RAB9A 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.